A new formulation of bevacizumab for neovascular age-related macular degeneration (nAMD) is headed for evaluation by the US Food and Drug Administration (FDA) amid controversy
We use cookies to ensure that we give you the best experience on our website. If you continue to use this site we will assume that you are happy with it.Ok
